Advertisement

Recognizing CADASIL: a Secondary Cause of Migraine with Aura

  • John Glenn Burkett
  • Carrie Dougherty
Uncommon and/or Unusual Headaches and Syndromes (J Ailani, Section Editor)
  • 558 Downloads
Part of the following topical collections:
  1. Topical Collection on Uncommon and/or Unusual Headaches and Syndromes

Abstract

Purpose of Review

CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) is an important disease to consider in the differential diagnosis of migraine with aura. This review examines current literature regarding migraine in CADASIL, as well as diagnostic and treatment modalities.

Recent Findings

Recent studies have shown that smoking is a modifiable risk factor for progression of CADASIL (Chabriat et al. in Stroke 47:4–11, 2015). Specific imaging changes and findings on clinical exam can predict disease progression. However, migraine symptoms often precede MRI changes (Guey et al. in Cephalalgia 36:1038–47, 2015). A recent paper on migraine treatment in CADASIL reevaluates the prevailing belief that vasoconstrictive abortive medications are contraindicated in these patients (Tan and Markus in PLoS ONE 11:e0157613, 2016).

Summary

CADASIL is an autosomal dominantly inherited vasculopathy causing ischemic pathology in younger individuals due to a mutation in the NOTCH3 gene. The mutation results in impaired arterial contractility due to accumulation of granular osmiophilic extracellular material (GOM) in vascular smooth muscle cells (VSMCs). Clinical manifestations include migraine with and without aura, cognitive decline, ischemic events, and mood disorders. The presenting symptom is often migraine with aura. Characteristic MRI changes are often present. Genetic screening is available to confirm NOTCH3 mutation and pathognomic changes are often seen in skin biopsy. Treatment of migraine is similar to the general population, but with some notable and specific differences. Further studies in CADASIL, other small vessel arteriopathies, and migraine may help us understand more about the pathophysiology of these conditions and help with treatment development.

Keywords

Migraine Aura CADASIL Arteriopathy Cerebral infarction Leukoencephalopathy NOTCH3 

Notes

Compliance with Ethical Standards

Conflict of Interest

Dr. John Glenn Burkett and Dr. Carrie Dougherty each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    • Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser M. CADASIL. Lancet Neurol. 2009;8:643–53. Comprehensive review article from 2009 discussing pathophysiology, symptoms, diagnosis, treatment and progression.CrossRefPubMedGoogle Scholar
  2. 2.
    Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996;383:707–10.CrossRefPubMedGoogle Scholar
  3. 3.
    • Tikka S, Baumann M, Siitonen M, et al. CADASIL and CARASIL. Brain Pathol. 2014;24:525–44. Recent article on the genetics and pathology of CADASIL and CARASIL.CrossRefPubMedGoogle Scholar
  4. 4.
    Kalimo H, Ruchoux M, Viitanen M, Kalaria R. CADASIL: a common form of hereditary arteriopathy causing brain infarcts and dementia. Brain Pathol. 2002;12:371–84.CrossRefPubMedGoogle Scholar
  5. 5.
    Joutel A, Andreux F, Gaulis S, Domenga V, Cecillon M, Battail N, et al. The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J Clin Investig. 2000;105:597–605.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Chabriat H, Vahedi K, Bousser M, et al. Clinical spectrum of CADASIL: a study of 7 families. Lancet. 1995;346:934–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Ruchoux M, Maurage C. CADASIL. J Neuropathol Exp Neurol. 1997;56:947–64.CrossRefPubMedGoogle Scholar
  8. 8.
    Dichgans M, Mayer M, Uttner I, Brüning R, Müller-Höcker J, Rungger G, et al. The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol. 1998;44:731–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Liem M, Oberstein S, van der Grond J, Ferrari M, Haan J. CADASIL and migraine: a narrative review. Cephalalgia. 2010;30:1284–9.CrossRefPubMedGoogle Scholar
  10. 10.
    • Guey S, Mawet J, Herve D, Duering M, Godin O, Jouvent E, et al. Prevalence and characteristics of migraine in CADASIL. Cephalalgia. 2015;36:1038–47. Prospective cohort of 378 CADASIL patients evaluating migraine symptoms and possible correlates with symptoms, severity and MRI findings.CrossRefGoogle Scholar
  11. 11.
    Gunda B, Herve D, Godin O, et al. Effects of gender on the phenotype of CADASIL. Stroke. 2011;43:137–41.CrossRefPubMedGoogle Scholar
  12. 12.
    •• Tan R, Markus H. CADASIL: migraine, encephalopathy, stroke and their inter-relationships. PLoS ONE. 2016;11:e0157613. Recently completed prospective study with 300 symptomatic CADASIL patients examining migraine patterns, treatment responses and associations between migraine, stroke and encephalopathy. First article to document use of vasoconstrictive treatment with triptans and ergots in CADASIL patients.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Adib-Samii P, Brice G, Martin R, Markus H. Clinical spectrum of CADASIL and the effect of cardiovascular risk factors on phenotype: study in 200 consecutively recruited individuals. Stroke. 2010;41:630–4.CrossRefPubMedGoogle Scholar
  14. 14.
    Vahedi K, Chabriat H, Levy C, Joutel A, Tournier-Lasserve E, Bousser M. Migraine with aura and brain magnetic resonance imaging abnormalities in patients with CADASIL. Arch Neurol. 2004. doi: 10.1001/archneur.61.8.1237.PubMedGoogle Scholar
  15. 15.
    • Zhu S, Nahas S. CADASIL: imaging characteristics and clinical correlation. Curr Pain Headache Rep. 2016. doi: 10.1007/s11916-016-0584-6. Recent article reviewing imaging findings in CADASIL and correlation with clinical symptoms.Google Scholar
  16. 16.
    Desmond D, Moroney J, Lynch T, Chan S, Chin S, Mohr J. The natural history of CADASIL : a pooled analysis of previously published cases. Stroke. 1999;30:1230–3.CrossRefPubMedGoogle Scholar
  17. 17.
    Liem M, Lesnik Oberstein S, Haan J, van der Neut I, van den Boom R, Ferrari M, et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: progression of MR abnormalities in prospective 7-year Follow-up Study. Radiology. 2008;249:964–71.CrossRefPubMedGoogle Scholar
  18. 18.
    Chabriat H, Mrissa R, Levy C, Vahedi K, Taillia H, Iba-Zizen M, et al. Brain stem MRI signal abnormalities in CADASIL. Stroke. 1999;30:457–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Viswanathan A. Blood pressure and haemoglobin A1c are associated with microhaemorrhage in CADASIL: a two-centre cohort study. Brain. 2006;129:2375–83.CrossRefPubMedGoogle Scholar
  20. 20.
    Peters N, Holtmannspotter M, Opherk C, Gschwendtner A, Herzog J, Samann P, et al. Brain volume changes in CADASIL: a serial MRI study in pure subcortical ischemic vascular disease. Neurology. 2006;66:1517–22.CrossRefPubMedGoogle Scholar
  21. 21.
    Peters N, Opherk C, Bergmann T, Castro M, Herzog J, Dichgans M. Spectrum of mutations in biopsy-proven CADASIL. Arch Neurol. 2005;62:1091.CrossRefPubMedGoogle Scholar
  22. 22.
    •• Chabriat H, Hervé D, Duering M, et al. Predictors of clinical worsening in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Stroke. 2015;47:4–11. Prospective cohort study of 290 CADASIL patients evaluating for demographic, clinical, and MRI predictors of stroke, dementia, clinical worsening and death. Underlines importance of imaging and exam in predicting disease progression and showed that smoking is a modifiable risk factor for progression.CrossRefPubMedGoogle Scholar
  23. 23.
    Forteza A, Brozman B, Rabinstein A, Romano J, Bradley W. Acetazolamide for the treatment of migraine with aura in CADASIL. Neurology. 2001;57:2144–5.CrossRefPubMedGoogle Scholar
  24. 24.
    • Donnini I, Nannucci S, Valenti R, Pescini F, Bianchi S, Inzitari D, et al. Acetazolamide for the prophylaxis of migraine in CADASIL: a preliminary experience. J Headache Pain. 2012;13:299–302. Retrospective study looking at 7 patients treated with acetazolamide for migraine prophylaxis and their responses.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    • Ferrari M, Klever R, Terwindt G, Ayata C, van den Maagdenberg A. Migraine pathophysiology: lessons from mouse models and human genetics. Lancet Neurol. 2015;14:65–80. Review article summarizing recent findings in mouse models and possible connections in humans in regards to migraine and aura pathophysiology.CrossRefPubMedGoogle Scholar
  26. 26.
    Brennan K, Beltran-Parrazal L, Lopez-Valdes H, Theriot J, Toga A, Charles A. Distinct vascular conduction with cortical spreading depression. J Neurophysiol. 2007;97:4143–51.CrossRefPubMedGoogle Scholar
  27. 27.
    Hadjikhani N, Sanchez del Rio M, Wu O, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci. 2001;98:4687–92.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Haffner C, Vinters H. CADASIL, CARASIL, CARASAL. Neurology. 2016;87:1752–3.CrossRefPubMedGoogle Scholar
  29. 29.
    Chabriat H, Tournier-Lasserve E, Vahedi K, et al. Autosomal dominant migraine with MRI white-matter abnormalities mapping to the CADASIL locus. Neurology. 1995;45:1086–91.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of NeurologyMedStar Georgetown University HospitalWashingtonUSA

Personalised recommendations